Abivax (ABVX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.69

Estimate

-$0.86

Surprise

-97.0%

Score today

4.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Abivax (ABVX) reported a wider loss than forecast — adjusted EPS of -$1.69 against the -$0.86 estimate (a 97.0% shortfall).

• BTIG Reiterates Buy on Abivax, Maintains $175 Price Target — benzinga, 2026-09-22
• These Analysts Slash Their Forecasts On Abivax Following H1 Results — benzinga, 2026-09-22
• Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151 — benzinga, 2026-09-22

TrendMatrix currently rates ABVX Sell at 4.6/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -97.0% surprise compares with a -77.8% four-quarter average. Next scheduled report: 2027-03-22.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$86.56

Price target

$142.68

Stop

$81.59

Upside to target

+64.8%

Reward-to-risk

6.8:1

Model outputs from TrendMatrix’s engine as of 2026-10-12 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$7.69B

P/E (fwd)

-22.7

52-week range

$69.81–$148.83

Off 52-week high

41.8%

RSI (14)

32

Volume vs avg

0.28×

Score today

4.6/10